UNSPSC 51171905: Cisapride

This classification denotes an antiemetic agent with the molecular formula C23H29ClFN3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UVL329170W, chemically known as benzamide, 4-amino-5-chloro-n-(1-(3-(4-fluorophenoxy)propyl)-3-methoxy-4-piperidinyl)-2-methoxy-, cis- but generally known as cisapride, which bears US NIH Compound Identifier 2769. European Medicines Agency schedules Cisapride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07479MIG.

UNSPSC 51171905 Cisapride, a Commodity code, nominally names a specific prokinetic pharmaceutical agent, but recent state and local activity under this code does not center on cisapride procurement. Instead, the code appears in solicitations spanning broader pharmaceutical and diagnostic testing services — including offender drug screening, direct-to-manufacturer prescription programs, and multi-source generic pharmaceutical distribution. State and local governments buying under this taxonomy are sourcing specimen collection and drug-testing lab services, pharmacy benefit program infrastructure, and wholesale pharmaceutical supply arrangements rather than cisapride as a line item. The issuing bodies include county criminal justice departments (Collin County Community Supervision and Corrections Department in Texas), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving state and local government facilities across multiple states including Oregon). The mismatch between the code's nominal scope and actual recent procurement suggests this Commodity code may be tagged inconsistently or serve as a placeholder for pharmaceutical and diagnostic-testing service categories that lack more precise UNSPSC alignment.

Recent activity is concentrated in Texas and Minnesota. Collin County posted RFP 2026-327 on July 9, 2026, soliciting offender specimen collection and drug testing services with proposals due July 23, 2026; the scope includes staffing two collection sites, lab testing at approximately 25,031 tests annually, electronic result reporting, and lab certification from SAMHSA, TX DPS, or CAP, with an estimated contract value of $600,000 and a term through September 1, 2026 plus three optional one-year renewals. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 (response deadline April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting between the state and pharmaceutical manufacturers outside traditional pharmacy benefit manager arrangements. MMCAP, administered by Minnesota's Office of State Procurement, posted RFP S1070000015802 on January 20, 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026. The code shows limited relevant recent activity; opportunities present appear to reflect pharmaceutical and diagnostic-testing services rather than cisapride specifically.